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Abstract
Purpose The present multimodal neuroimaging study exam-
ined whether amyloid pathology and glucose metabolism are
related to cortical volume loss over time in Alzheimer’s dis-
ease (AD) patients and healthy elderly controls.
Methods Structural MRI scans of eleven AD patients and ten
controls were available at baseline and follow-up (mean interval
2.5 years). Change in brain structure over time was defined as
percent change of cortical volume within seven a-priori defined
regions that typically show the strongest structural loss in AD. In
addition, two PET scans were performed at baseline: [11C]PIB to
assess amyloid-β plaque load and [18F]FDG to assess glucose
metabolism. [11C]PIB binding and [18F]FDG uptake were mea-
sured in the precuneus, a region inwhich both amyloid deposition
and glucose hypometabolism occur early in the course of AD.
Results While amyloid-β plaque load at baseline was not
related to cortical volume loss over time in either group, glucose
metabolism within the group of AD patients was significantly
related to volume loss over time (rho=0.56, p<0.05).
Conclusion The present study shows that in a group of AD
patients amyloid-β plaque load as measured by [11C]PIB
behaves as a trait marker (i.e., all AD patients showed elevated
levels of amyloid, not related to subsequent disease course),
whilst hypometabolism as measured by [18F]FDG changed
over time indicating that it could serve as a state marker that is
predictive of neurodegeneration.
Keywords Alzheimer’s disease . Amyloid plaques .
Hypometabolism . Atrophy . Longitudinal study
Introduction
Several biomarkers are in use for clinical research into
Alzheimer’s disease (AD), both for diagnosis and for monitoring
disease [1]. Recently, an updated version of the biomarker accu-
mulation model has been proposed by Jack and colleagues [2],
postulating a temporal cascade of several biomarkers, including
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accumulation of amyloid-beta and hyperphosphorylated tau, re-
gional specific hypometabolism, structural loss, and finally cog-
nitive decline. This model is based on the hypothesis that these
biomarkers change in an ordered manner, eventually resulting in
clinical AD. Hypometabolism and structural loss follow a similar
temporal pattern, and continue to change substantially in the
clinical phase of AD [2].
Understanding how AD biomarkers behave over time and
how they are related to each other is crucial in understanding
underlying mechanisms of the disease. In addition, it is rele-
vant for the development of therapeutic interventions. Volu-
metric brain changes, measured using structural MRI, are well
validated biomarkers in AD research. Indeed, volume loss has
been found to correlate strongly with disease severity even at
the later stages of the disease [3, 4]. However, little is known
about the relationship betweenmolecular markers of AD, such
as amyloid-β plaque load and hypometabolism, on the one
hand and brain volume loss over time on the other.
A leading theory proposes that amyloid-β plaque forma-
tion is the main initiator of AD [5, 6]. Amyloid-β can be
measured in vivo using carbon-11 labelled Pittsburgh com-
pound B ([11C]PIB) positron emission tomography (PET) [7].
Elevated levels of [11C]PIB binding in the posterior cingulate
cortex/precuneus can be seen in prodromal AD, spreading
throughout the entire association cortex at later stages [8, 9].
Amyloid-beta accumulation is commonly believed to stagnate
in the clinical phase of the disease, i.e., in the stage where
patients meet criteria for clinical AD [3, 10–12]. However,
some studies do report slow, but continuous, build-up of
amyloid-plaques in AD patients [13, 14].
Brainmetabolism can bemeasured using fluorine-18 labelled
fluorodeoxyglucose ([18F]FDG) and PET, and is an indicator of
neuronal function [15, 16]. Hypometabolism in the precuneus is
already observed in the preclinical stage of AD [17–19] and
becomes even more pronounced in the clinical phase [20]. Both
hypometabolism and brain volume loss progressively worsen
throughout the different disease stages [2].
The purpose of the present multimodal neuroimaging study
was to examine whether amyloid pathology and glucose me-
tabolism are related to cortical volume loss over time in both
AD patients and normal controls. As different biomarkers are
believed to approach pathological levels at different times
during the disease process, associations between biomarkers
are expected to change with disease progression.
Methods
Participants
All participants received a standard dementia screening, which
included obtaining a record of their medical history, neuropsy-
chological testing, physical and neurological examination,
structural MRI and screening laboratory tests. Patients were
excluded when they had a history of major psychiatric or
neurological illness other than AD, used non-steroidal anti-
inflammatory drugs, or showed clinically significant abnormal-
ities other than AD based on the MRI scan as determined by a
neuroradiologist. Additional exclusion criteria for normal con-
trols were subjective complaints and a positive [11C]PIB scan at
baseline. TheMiniMental State Examination (MMSE) was part
of neuropsychological testing [21]. Clinical diagnosis was
established by a multidisciplinary team, both at baseline and at
follow-up. Follow-up of patients was planned after approxi-
mately 2–3 years. There were three patients with mild cognitive
impairment (MCI) [22] at baseline, who were diagnosed with
probable AD [23] at follow-up. These patients were included in
the final AD group (n=11) that was compared with an elderly
control group (n=10). Longitudinal PET data were available for
nine AD patients and ten controls, after an average of 2.5 years.
Findings of this longitudinal PET study have been reported
previously [11]. In the present study, only baseline PET data
are reported, as the purpose was to assess whether baseline PET
data are related to ongoing structural loss, i.e., can be used to
predict future atrophy. LongitudinalMRI data were available for
all subjects and were, on average, acquired 2.5 years after the
baseline scan (Table 1). The study was approved by theMedical
Ethics ReviewCommittee of theVUUniversityMedical Center.
Written informed consent was obtained from subjects and/or
Table 1 Participant demographics, cortical volume in the AD-signature
regions, [11C]PIB binding (BPND) and [
18F]FDG uptake (SUVr) in the
precuneus, and MMSE score at baseline in normal controls (NC) and




Age at baseline (Years) 65.80±7.39 62.82±6.23
Time between baseline and follow-
up (Years)
2.44±0.28 2.64±0.59
Cortical volume at baseline (mm3)* 1006.89±151.97 931.02±91.81
Cortical volume loss over time (%)* 0.64±1.06 3.45±1.51
Precuneus volume at baseline (mm3) 907.1±124.80 902.20±177.30
[11C]PIB BPND in precuneus at
baseline*
0.04±0.06 0.77±0.15
[11C]PIB BPND (PVC) in precuneus
at baseline*
0.02±0.05 0.54±0.17
[18F]FDG SUVr in precuneus at
baseline
1.07±0.08 1.01±0.12
[18F]FDG SUVr (PVC) in precuneus
at baseline
1.03±0.08 0.97±0.13
MMSE score at baseline* 29.40±0.52 25.45±2.42
Data are presented as means ± standard deviations (SD) * represents
p<0.05, [11C]PIB carbon-11 labeled Pittsburgh compound B, measuring
amyloid-β. [18F]FDG fluorine-18 labeled fluorodeoxyglucose, measur-
ing brain metabolism. PVC partial volume correction. PBND non-dis-
placeable binding potential. SUVr standardized uptake value ratio
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subjects’ caregivers after complete written and verbal descrip-
tion of the study.
MRI protocol
All subjects underwent structural MRI using a 1.5 T Sonata
scanner (Siemens Medical Solutions, Erlangen, Germany).
The scanning protocol included a coronal T1-weighted 3-
dimensional magnetization-prepared rapid-acquisition gradi-
ent echo (MPRAGE) image (echo time 3.97 ms; repetition
time 2,700 ms; inversion time 950 ms; flip angle 8°; 160
coronal slices; voxel size 1×1.5×1 mm3).
PET protocol
Both [11C]PIB and [18F]FDG scans were acquired using an
ECAT EXACT HR + scanner (Siemens/CTI, Knoxville,
USA). The properties of this scanner have been reported
elsewhere [24]. A head holder was used to restrict patient
movement and head movement was checked on a regular
basis. For the [11C]PIB scan, first a 10- min transmission scan
was performed (to correct for photon attenuation), which was
followed by a dynamic emission scan of 90 min. For the
[18F]FDG scan, subjects rested for 10 min with eyes closed
in a dimly lit room and with minimal background noise when
[18F]FDG was injected. Thirty-five minutes later, patients
underwent a 10-min transmission scan followed by a 15-min
(static) emission scan. Further details of [11C]PIB and
[18F]FDG scans can be found elsewhere [11]. The maximum
interval between [18F]FDG and [11C]PIB scans was 1 month.
MRI analysis
To extract reliable volume estimates, images were processed
using the longitudinal stream in Freesurfer that is explained in
detail elsewhere [25]. Briefly, an unbiased within-subject tem-
plate space and image was created using robust inverse consis-
tent registration. Several processing steps, such as skull strip-
ping, and atlas registration as well as creation of spherical
surface maps and grey matter segmentations were then initial-
ized with common information from the within-subject tem-
plate, significantly increasing reliability and statistical power.
Volumetric brain changes were assessed in seven a-priori de-
fined regions of interest (ROIs) that are known to be susceptible
to AD related atrophy [26]. These regions were situated in the
inferior frontal cortex, posterior cingulate cortex, temporal polar
cortex, lateral temporal cortex, inferior parietal sulcus, inferior
parietal cortex and medial temporal lobe (see Fig. 1a), which
can be downloaded freely as Freesurfer surface labels (http://
surfer.nmr.mgh.harvard.edu/fswiki/Chubs). The labels were
mapped to the brain of each participant using surface based
registration as implemented in Freesurfer [27]. The mean
volume within these seven ROIs was calculated for both
hemispheres of each subject at baseline and at follow-up. The
percent change of volume within each ROI was calculated by
dividing the rate of change in volume by the temporal average
within these ROIs (symmetrized percent change). Initial results
showed that the percent change within these seven regions for
left and right hemispheres were highly correlated (rho=0.88,
p<0.01) and, therefore, mean percent change across both hemi-
spheres was used in all analyses. To test whether results for
these regions were specific for AD, a second control analysis
was performedmeasuring brain volume in an ROI consisting of
primary motor and sensory regions (precentral and postcentral
gyri), as these regions are thought to be relatively spared in
early and mid-stages of AD [28].
PET analysis
Standard preprocessing of PET data was performed [11]. Struc-
tural T1 images were aligned to corresponding PET images
using a mutual information algorithm. Data were analyzed
using PVE-lab, a software program that makes use of a prob-
ability map based on 35 defined ROIs [29]. Results are reported
with and without partial volume correction (PVC), because at
present there is no consensus on how to optimally perform PVC
of PET data [30]. PVC based on iterative deconvolution [31]
was used with a Gaussian kernel of 7 mm FWHM and ten
iterations. The deconvolution method was applied with a Gibbs
prior (neighbourhood of 1 voxel and weight of 0.15). Iterative
deconvolution is PET based, does not make use of the MR
images, and improves spatial resolution and contrast. It uses the
point spread function (PSF) of the PET system to sharpen the
PETscan iteratively. The advantage of the deconvolution meth-
od is that it is free of segmentation or co-registration errors and
unaffected by tracer uptake heterogeneity [31]. Results with and
without partial volume correction will further be referred to as
“with PVC” and “without PCV”. Parametric images of non-
displaceable binding potential (BPND), a quantitative measure
of specific binding, of [11C]PIB were generated using a 2-step
basis function implementation of the simplified reference tissue
model with cerebellar grey matter as reference tissue (RPM2)
[32, 33]. If global cortical [11C]PIB BPNDwas higher than 0.54,
subjects were considered to be PIB-positive [9]. For [18F]FDG,
parametric images of standardized uptake value ratio (SUVr),
using cerebellar grey matter as reference, were extracted from
the interval between 45 and 60 min after injection. Cerebellar
grey matter lacks Congo red and thioflavin-S positive plaques
and was, therefore, chosen as reference tissue for analysis of
both [11C]PIB and [18F]FDG data [34].
[11C]PIB and [18F]FDG binding in ROIs
Both parametric PET images (i.e., [11C]PIB BPND and
[18F]FDG SUVr) were registered to standard space (MNI
152), using 12° of freedom (DOF) linear translation (FLIRT,
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FSL version 4.1; www.fmrib.ox.ac.uk/fsl). Structural T1
scans were segmented into cerebrospinal fluid, grey matter
andwhite matter using FSL [35]. Average binding of [11C]PIB
and average uptake of [18F]FDG were then calculated for the
precuneus (including only grey matter) based on the Harvard-
Oxford cortical atlas (provided in FSL; http://www.cma.mgh.
harvard.edu/fsl_atlas.html). The precuneus was chosen
because both amyloid-plaque formation and glucose
hypometabolism occur in this region relatively early in the
course of the disease [8, 17]. At baseline, precuneus volume
was not significantly associated with [18F]FDG uptake in the
precuneus (AD no PVC; rho=0.36, p=0.14; AD with PVC;
rho=0.32, p=0.17. NC no PVC; rho=0.46, p=0.09 NC with
PVC; rho=0.38, p=0.14), suggesting that observed
hypometabolism is not due to partial volume effects.
Statistical analysis
All other subsequent statistical analyses were performed using
SPSS (version 15.0; SPSS, Chicago, IL, USA). Differences in
gender distribution between AD patients and controls were
assessed using a Chi-square test. Differences in age, time
between baseline and follow-up, [11C]PIB BPND, [
18F]FDG
SUVr and MMSE score between AD patients and controls
were examined using a one-way ANOVA. Differences in
cross-sectional measures of cortical volume (baseline and
follow-up) between controls and AD patients were assessed
using an ANOVAwith intracranial volume and age as covar-
iates. Differences in percent change over time in cortical
volume between controls and AD patients were assessed with
an ANOVAwith age as covariate. Spearman correlation coef-
ficients between modalities were tested one-tailed because of
the a-priori expected directionality of these associations. A p-
value below 0.05 was considered statistically significant.
Results
Subject demographics are given in Table 1. Distribution of
gender (X2(1)=0.51, p=0.48), age (F(1,20)=1.01, p=0.33),
and time between baseline and follow-up (F(1,20)=1.04, p=
0.32) did not differ significantly between AD patients and
controls. Cross sectional analysis indicated that cortical vol-
ume within a priori selected AD-signature regions was signif-
icantly lower in AD patients compared with normal controls at
both baseline (F(1,17)=5.15, p<0.05) and follow-up
(F(1,17)=6.78, p<0.05) (see Fig. 1b).
Longitudinal analysis revealed that AD patients showed
significantly more cortical volume loss over time (mean vol-
ume loss 3.5 %) than normal controls (0.6%) (F(1,18)=20.51,
p<0.01), confirming expected progression of atrophy over
time in the AD group. There was no significant difference
between AD patients and controls in percent change of corti-
cal volume in primary motor and sensory cortices (F(3,18)=
Fig. 1 The a priori selected
regions of interest [27] are shown
on an average Freesurfer surface,
left hemisphere, and are situated
in the inferior frontal cortex,
posterior cingulate cortex,
temporalpolar cortex, lateral
temporal cortex, inferior parietal
sulcus, inferior parietal cortex and
the medial temporal lobe (a).
Patients with Alzheimer’s disease
(AD) showed reduced cortical
volume when compared to
normal controls (NC) at both
baseline and follow-up. Cortical
volume within the AD-signature
regions is displayed for each
subject on the y-axis. Age at
baseline and follow-up is
represented on the x-axis (b)
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0.29, p=0.48), regions that are known to be relatively spared
in early andmid-stages of Alzheimer’s disease [29], indicating
that results were unlikely due to systematic measurement
errors.
Table 1 provides baseline measures of [11C]PIB BPND,
[18F]FDG SUVr in the precuneus (with and without PVC),
together with MMSE scores, in AD patients and controls. As
expected on the basis of the selection criteria for both groups,
at baseline, [11C]PIB BPND was significantly higher (no PVC:
F(1,20)=207.24, p<0.01) (with PVC: F(1,20)=82,66,
p<0.01) and the MMSE score was significantly lower
(F(1,20)=25.35, p<0.01) in AD patients than in controls.
Although [18F]FDG SUVr at baseline was reduced in AD
patients compared with controls, this was not significant (no
PVC: F(1,20)=1.58, p=0.22) (with PVC: F(1,20)=1.24, p=
0.28). [11C]PIB binding at baseline was not related to cortical
volume loss over time in either group (Fig. 2A and A′). In
contrast, [18F]FDG SUVr with PVC at baseline was signifi-
cantly related to volume loss over time in AD patients (rho=
0.58, p<0.05) (Fig. 2B′). Similar results were found when no
PVC was applied, although this was not significant (rho=
0.52, p=0.05) (Fig. 2B). The relationship was such that AD
patients with the lowest metabolism at baseline showed the
most subsequent loss of cortical volume over time. No asso-
ciation of [18F]FDG SUVr with volume loss over time was
found in controls (no PVC: rho=−0.19 p=0.30) (with PVC:
rho=−0.36, p=0.16). An overview of various Spearman cor-
relation coefficients for each group is given in Table 2.
Discussion
The main finding of this study was the observed association
between [18F]FDG uptake in the precuneus at baseline and
volume loss over time in AD patients indicating that low
metabolism at baseline is related to more subsequent cortical
volume loss over time. This association was not observed in
normal controls. In addition, [11C]PIB binding at baseline was
not related to cortical volume loss over time in the AD group
nor in the control group.
Fig. 2 Alzheimer’s disease (AD) patients with lowest metabolism at
baseline showed the most subsequent loss of cortical volume over time.
The associations of cortical volume loss over time with amyloid deposi-
tion and metabolism in the precuneus at baseline is displayed for normal
controls (NC) and patients with AD. Results without and with partial
volume correction (PVC) are displayed. Percent change in cortical vol-
ume over time is depicted on the y-axis of all panels. [11C]PIB binding in
the precuneus at baseline without PVC (A) and with PVC (A′) and
[18F]FDG retention in the precuneus at baseline without PVC (B) and
with PVC (B′) is shown on the x-axis. [11C]PIB binding at baseline was
not related to cortical volume loss over time in either group while
[18]FDG uptake with PVC was significantly related to volume loss over
time in AD patients only. Spearman correlation coefficients (ρ) are
reported (p-value)
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The lack of association between [11C]PIB binding and
cortical volume loss over time in the AD group is in agreement
with prior cross-sectional studies using [11C]PIB binding [36]
and levels of amyloid in cerebral spinal fluid [37]. This
indicates that amyloid-plaque formation already has reached
a plateau in these patients [3, 10, 11, 38]. However, some
research does indicate a continued build-up of amyloid-
plaques in AD patients [13]. This might explain why some
studies show a relationship between amyloid and atrophy rates
[39]. Similar to this study, Tosun and colleagues [39] exam-
ined baseline amyloid formation with volumetric changes
over time, but included MCI patients. Also in contrast to this
study, they did not select a priori regions, but used parallel
independent component analysis, allowing for an unbiased
search for (spatially unrelated) associations between
amyloid-β and atrophy rates. They concluded that the spatial
distribution of increased amyloid-β and the related spatial
atrophy rates were in line with regions known to be vulnerable
for Alzheimer’s disease pathology. These results are conflict-
ing with the present study. This could be explained by the fact
that MCI patients might not have reached a plateau in
amyloid-β formation unlike AD patients in this study, or by
incorporating a more sensitive voxelwise approach. The ab-
sence of an association in our sample of AD patients could
also be evidence that amyloid-plaque formation is not directly
related to ongoing structural loss, but is mediated by other
‘downstream’ factors such as hypometabolism or neurofibril-
lary tangle formation [6, 36]. With respect to the control
group, also no correlation between cortical volume loss over
time and amyloid load was found. This was in agreement with
our hypothesis; only healthy controls that were PIB negative
at baseline were included and were, therefore, believed to
show no early neurodegeneration. Regarding the relationship
between amyloid and structural loss in healthy elderly there is
no consensus in the literature; some studies find associations
between atrophy and amyloid load in healthy elderly [36, 40,
41], while others do not [42, 43]. When PIB positive controls
are included, controls with very early AD pathology might
drive the association between amyloid load and structural loss.
An association between amyloid load and regional atrophy
has been reported in PIB positive healthy elderly, while this
was not found in PIB negative elderly [44, 45].
The finding that [18F]FDG uptake was related to volume
loss over time in AD patients is in line with prior cross-
sectional studies [46–49]. Whilst these results do not establish
a causal relationship between neuronal dysfunction and atro-
phy, the fact that metabolism at baseline is related the subse-
quent atrophy can be interpreted as support for the hypothesis
that neuronal dysfunction, as indicated by low [18F]FDG,
precedes structural loss [2]. Since this association was stron-
ger after PVC, and baseline cortical volume was not associat-
ed with ongoing structural loss in AD patients, it is believed
that hypometabolism provides more information than atrophy
alone. This is supported by the finding that hypometabolism
exceeds atrophy in AD patients when examining spatial over-
lap [50]. Since amyloid is shown to precede hypometabolism
in early AD [51], this also explains why, in contrast to AD
patients, we found no association between hypometabolism
and volume loss over time in normal controls.
It has been reasoned that hypometabolism may be the medi-
ating factor that links amyloid-plaque formation to ongoing
structural loss. In cognitively normal elderly controls, it was
found that abnormal levels ofβ-amyloid accompanied by a brain
injury marker (hypometabolism or atrophy) resulted in higher
rates of ongoing structural changes [52]. The associations of AD-
biomarkers may be different within disease stages. It has been
shown that metabolism (briefly) increases together with amyloid
burden in MCI patients [53], perhaps serving as a compensatory
mechanism. A different causal mechanism has been postulated
for early AD patients: higher metabolism, especially in ‘hub’
regions, was linked to higher amyloid-β accumulation over time
[54], which is in line with evidence from cellular investigations
[55]. Future studies might focus on the longitudinal relationship
between amyloid, metabolism and atrophy across different
stages of AD, preferably incorporating multiple follow-up scans,
in order to investigate the complex relationship between
hypometabolism, amyloid accumulation and atrophy.
Future recommendations and limitations
Although the present results illustrate the feasibility of state of
the art multi-modal longitudinal neuroimaging methods, the
Table 2 Associations of cortical volume change over time in AD-signa-
ture regions with cortical volume at baseline, [11C]PIB binding (BPND)
and [18F]FDG uptake (SUVr) in the precuneus at baseline, and MMSE
score at baseline in both normal controls (NC) and patients with
Alzheimer’s disease (AD)
Cortical volume change over time
NC AD
Cortical volume at baseline 0.69 (p=0.01)* 0.26 (p=0.22)
Precuneus volume at baseline 0.01 (p=0.49) 0.09 (p=0.40)
[11C]PIB BPND in precuneus
at baseline
−0.38 (p=0.14) −0.26 (p=0.22)
[11C]PIB BPND (PVC) in
precuneus at baseline
−0.10 (p=0.39) 0.13 (p=0.36)
[18F]FDG SUVr in precuneus
at baseline
−0.19 (p=0.30) 0.52 (p=0.051)
[18F]FDG SUVr (PVC) in
precuneus at baseline
−0.36 (p=0.16) 0.58 (p=0.03)*
MMSE score at baseline 0.14 (p=0.35) −0.06 (p=0.43)
Data are presented as 1-tailed Spearman correlation coefficients with
corresponding p-values, * represents p<0.05, [11C]PIB carbon-11 la-
beled Pittsburgh compound B, measuring amyloid-β. [18]FDG fluo-
rine-18 labeled fluorodeoxyglucose, measuring brain metabolism. PVC
partial volume correction. PBND non-displaceable binding potential.
SUVr standardized uptake value ratio
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study also had limitations. The major limitation was the lim-
ited sample size. Still, even with the small sample, results are
in line with the hierarchical biomarker model [2]. Another
limitation was the fact that only AD patients with both a
baseline and a follow-up MRI scan were included in the
present study, which may have lead to exclusion of patients
in more advanced stages of the disease and possibly limits the
generalisability of the results. Also, the control group was
specifically selected to be PIB negative in order ensure a clear
difference between groups in terms of amyloid-ß neuropathol-
ogy, which limits generalisability to populations where
amyloid-ß status is unknown. To fully test current models of
the development of different biomarkers, inclusion of PIB
positive clinically normal older adults will be necessary and
longer follow-up time with more measurement occasions are
needed. Three patients in the AD group were initially defined
as MCI patients. Since these MCI patients progressed to AD
after clinical diagnosis at follow-up, these subjects were clas-
sified as probable AD. All MCI patients were PIB-positive at
baseline, similar to all AD patients. Inclusion of these three
MCI patients to our probable AD group may have influenced
our results, since AD patients have more progressed neurode-
generation than MCI patients. We chose for an inclusive
approach for the present study to increase our sample size.
In addition, in this longitudinal study structural images were
acquired on a 1.5 T MR system. It is possible that accuracy of
atrophy estimates could be improved by using an MR scanner
with a higher field strength, as this is associated with higher
spatial resolution. However, volumetry measurements on MR
scanners with different field-strengths (1.5 T vs. 3 T) have
been reported to be interchangeable [56], not exceeding
within-scanner measurement error [57]. Finally, the precuneus
was selected as ROI for both PETmeasures since this region is
vu lne rab l e fo r bo th amy lo id -β fo rma t ion and
hypometabolism [8, 17]. It should be noted that this implies
that results should not be generalised to other regions in the
brain. A voxel-wise approach would be needed to assess
whether other vulnerable regions exist. This will need to be
carried out in future studies, as the sample size of the present
study was too small for such an analysis.
Conclusion
In conclusion, the present study shows the feasibility of
assessing significant relationships between multiple neuroim-
aging modalities and can, therefore, be considered as a proof-
of-concept study for multimodal neuroimaging initiatives in
the spectrum of normal aging, mild cognitive impairment, and
AD. The present results show that, in a group of AD patients,
amyloid load as measured by [11C]PIB behaves as a trait
marker (i.e., all AD patients show elevated levels of amyloid
not related to rate of subsequent neurodegeneration). By
contrast, rate of hypometabolism in (preclinical) AD as mea-
sured by [18F]FDG can serve as a state marker that is predic-
tive of neurodegeneration.
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